Its expression has been shown to inversely correlate with HCC tumor size and disease stage in a genome-wide expression analysis (18, 19), consistent with preclinical data demonstrating that loss of ESR1 accelerates carcinogenesis. This evidence concerns the gene ESR1 and hepatocellular carcinoma.